Introduction: Aortic insufficiency (AR) evolves during follow-up with dilation of the left chambers and eventually with deterioration of the ejection fraction (EF). Treatment as well as evolution of EF after the procedure remains uncertain. The objective of the following work was to establish the prevalence of ventricular dysfunction and evaluate the evolution of EF at 6 months in patients with aortic valve replacement (AVR) due to AR.
View Article and Find Full Text PDFObjectives: Patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience poor outcomes due to the development of heart failure (HF). Tricuspid regurgitation (TR) has been found to be correlated with adverse outcomes in patients with HF. This study aims to assess whether the presence of significant TR is associated to adverse cardiac outcomes in patients diagnosed with ATTR-CM.
View Article and Find Full Text PDFIntroduction: Limited information exists on the prevalence and outcomes of patients undergoing surgical aortic valve replacement (SAVR) for aortic stenosis (AS) with reduced left ventricular ejection fraction (LVEF). This study aims to describe the number of AS patients undergoing SAVR with LVEF less than 55 % and quantify LVEF improvement at follow-up.
Material And Methods: We analyzed patients undergoing SAVR with LVEF less than 55 % and the number of patients that improved the LVEF at 6 months.
Myocarditis is an inflammatory disease of the cardiac tissue of variable etiology, both infectious and non-infectious. Its presentation can range from asymptomatic to fulminant forms. We present the case of a 24-year-old male patient with a history of autoimmune hepatitis in compensated cirrhotic phase.
View Article and Find Full Text PDFBackground: Interleukin-1 blockade with anakinra reduces C-reactive protein (CRP) levels and prevents heart failure (HF) events after ST-segment myocardial infarction (STEMI). The effectiveness of anakinra according to the degree of systemic inflammation in STEMI has not been addressed.
Methods: We analyzed 139 patients from three Virginia Commonwealth University Anakinra Response Trial randomized clinical trials to assess whether CRP levels predicted HF hospitalization or death in patients with STEMI, and if CRP levels influenced the effects of treatment with anakinra.
Objective: The objective of this study was to describe the clinical and imaging characteristics and the evolution of heart transplantation patients due to anthracycline-induced cardiomyopathy.
Methods: Patients with a diagnosis of ACM who received a heart transplantation in our institution in the period of November 2009-April 2021 were included. Clinical characteristics, pre-transplant studies, and clinical outcomes after transplantation were collected retrospectively from the electronic medical record.
Light chain amyloidosis (AL) is a rare and underdiagnosed disease. The best treatment available is autologous bone marrow transplantation (BMT). Cardiac involvement is the main prognostic determinant in this pathology and sometimes an impediment to receive BMT.
View Article and Find Full Text PDFIntroduction: Mortality of infective endocarditis (IE) in Argentina continues to be high. The aim objective was to describe the clinical characteristics and identify factors associated with in-hospital and long-term mortality in patients with native valve IE.
Methods: Retrospective cohort study including adult patients with diagnosis of native valve IE, hospitalized during 2011-2021.
Takotsubo syndrome is a generally reversible cardiomyopathy often related to a stressor trigger, either physical or emotional. It is estimated that this entity represents between 1 and 6% of the cases of suspected acute coronary syndrome without ST segment elevation in women. Coexistence with coronary artery disease has been a matter of long controversy.
View Article and Find Full Text PDFObjective: To describe the clinical and imaging characteristics of heart transplantation patients due to amyloidosis in a community institution.
Method: Descriptive case series of consecutive heart transplantation patients with amyloidosis in a medical center. All patients with diagnosis of amyloidosis with cardiac compromise receiving heart transplantation, performed in the period November 2008 to February 2021, were included in the analysis.